JCM | Free Full-Text | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers | HTML
Mechanism of action of PARP inhibitors and synthetic lethality. Adapted... | Download Scientific Diagram
Rubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer | Business Wire
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Mechanism of action of PARPs. | Download Scientific Diagram
Rubraca (rucaparib) for the Treatment of Advanced Ovarian Cancer - Clinical Trials Arena
Role of PARP Inhibitors in BRCA-Related Malignancies
Additional mechanisms of action of PARPi. (a) In the presence of PARPi,... | Download Scientific Diagram
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
HR Deficiency & Response to PARPi Therapy | Rubraca® (rucaparib) tablets
Form 8-K MEDIVATION, INC. For: Jan 25
Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy | Future Oncology
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer - ScienceDirect
Rucaparib – second PARP inhibitor hits the market for ovarian cancer | MDedge Hematology and Oncology
AstraZeneca-Merck & Co.'s Lynparza gets EU approval in prostate cancer | S&P Global Market Intelligence
PARP inhibitors in ovarian cancer
Nausea and Vomiting: Managing Side Effects From PARP Inhibitors
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Rubraca® (rucaparib) tablets Rubraca MOA
Rubraca® (rucaparib) tablets Rubraca MOA
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity - Porcelli - 2013 - Molecular Oncology - Wiley Online Library
PARP Inhibitors: Where Are We in 2020 and What's Coming Next?
New Drug Product: Rubraca - MPR
PARP inhibitors in cancer treatment | OncologyPRO
